Plasmonics is expected to make a tremendous impact in the field of life sciences, with applications in bioimaging, biosensing, targeted delivery and externally-triggered locoregional therapy.  Plasmonic biosensors are considered to be highly promising for the development of simple, portable, sensitive, on-chip biodiagnostics for resource-limited settings such as at-home care, rural clinics, developing countries with low and moderate incomes and battle-field.  Point-of-care screening and quantification of target biomarkers can result in early diagnosis of renal cancers to improve patient survival for timely medical intervention at an early stage.  We demonstrate highly sensitive and specific detection of perilipin-2, a specific biomarker of kidney cancer, in patient urine samples using plasmonic paper-based biosensors.  The plasmonic biosensors are based on antibody-conjugated gold nanorattles. The limit of detection was found to be 50 pg/ml and encompassed five orders of magnitude of perilipin-2. The assay clearly differentiates patients with clear cell and papillary kidney cancers from control patients, and can be completed within 2 hours. This bioplasmonic paper is compatible with urine samples over the pH range of 5.0 to 8.5 and is not interfered by albuminuria or hematuria. This screening assay is a viable candidate for the fast, sensitive, cost-effective differential diagnosis of imaged renal masses. We will also describe plasmonic biosensors based on silk and metal-organic frameworks as protective coatings to stabilize natural antibodies bound to nanotransducers against thermal denaturation and loss of biorecognition.

Plasmonic paper for the detection of renal cancer in point-of-care and resource-limited settings

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.